http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진행성 비소세포폐암에 대한 2차 화학요법으로 paclitaxel과 cisplatin의 제 2상 임상연구
서영태,김봉석,고지영,최동석,최성호,김혜진,안영미,노용호,이경희 영남대학교 의과대학 2004 Yeungnam University Journal of Medicine Vol.21 No.2
gemcitabine과 carboplatin으로 치료받은 경력이 있는 진행성 비소세포폐암 환자 25명을 대상으로 2차 화학요법으로 paclitaxel과 cisplatin을 사용하여 다음과 같은 결과를 확인하였다. 전체 25명 중 5명에서 부분반응이 관찰되었으며, 반응군의 반응지속기간은 2~11개월로 중앙값 4.3개월이었다. 전체 환자의 무진행생존기간은 0~11개월로 중앙값 3.3개월이었으며, 생존기간은 1.3~39개월로 중앙값 7.4개월이었다. 전체 83회의 화학요법 중 WHO 3도의 혈소판감소증이 1회에서만 관찰되었으며, 비혈액학적 부작용도 감내할 만 하였다. 이상의 결과, paclitaxel과 cisplatin 복합화학요법은 진행성 비소세포폐암 환자에서 2차 요법으로 사용하였을 때 부작용이 적으며 효과적인 치료법의 하나로 판단된다. Background: To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. Subjects and Methods: Twenty-five patients were enrolled. The patients received 200 mg/㎡ paclitaxel as a 3-hour intravenous infusion and 60 mg/㎡ cisplatin as 30-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles. Results: All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20%(95% confidence interval, 4%~36%) and the median response duration was 4.5(range, 2-11) months. The median time to progression was 3.3(range, 0-14) months. The median overall survival of all patients was 7.4(range, 1.3-39) months. The hematologic toxicities were minor and easily controlled. Conclusion: The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.
Tripledecker 착물, (CpCo)_2(C_4R_4)과 Alkyne과의 반응
嚴在國,李元植,金碩峯,車震淳,李炯秀,李東鎬,金洪碩,沈相喆 대구효성가톨릭대학교 자연과학연구소 1993 基礎科學硏究論集 Vol.1993 No.1
트리플데카 착물류, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt들은 Jonas시약과 2-hexyne 또는 3-hexyne을 실온에서 동량으로 반응시킬때, 50% 이상의 최대 수율이 얻어졌다. 한 종류의 트리플데카 착물인 bis-(η^5-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt(13)는 실온에서 3-hexyne과 반응시키면, 착물 (η^5-cyclopentadienyl)cobalt-acyclopentadiene-μ-(η^4-2,4-cobaltacyclope-ntadiene)(η^5-cyclopentadienyl)cobalt(15)로 이성화되었다. 다른 한 종류의 트리플데카 착물, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,3-dimethyl-2,4-dipropyl-cyclobutadiene)dicobalt(14)를 2-hexyne 과 반응시켰더니 1,3,5-tri-methyl-2,4,6-tripropyl benzene화합물이 생성되었다. The tripledecker complexes, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt were produced by the reaction of Jonas reagent with 2-hexyne and 3-hexyne in the maxi-mum yield(above 50%) when they were reacted in eq-molar amounts at room temperature. A tripledecker complexes,bis-(η^2-cyclopentadienyl)-μ-(η^4-1,2,3,4-tetraalkylcyclobutadiene)dicobalt(13) was isomerized to (η^5-cyclopentadienyl)cobalt-acyclopentadiene-μ-(η^4-2,4-cobaltacyclope-ntadiene)(η^5-cyclopentadienyl)cobalt(15) on reacting with 3-hexyne at room temperature. Another tripledecker complex, bis-(η^5-cyclopentadienyl)-μ-(η^4-1,3-dimethyl-2,4-dipropyl-cyclobutadiene)dicobalt(14) was decomposed to give 1,3,5-trimethyl-2,4,6-trip-ropylbenzene through an intermediate complex by the reaction of 2-hexyne.
한국어판 예일 틱 증상 평가척도 : 신뢰도 및 타당도 연구
정선주,이정섭,유태익,구영진,전성일,김봉석,홍강의 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.5
목 적 : 틱 증상의 심한 정도를 평가하기 위한 도구인 예일 틱 증상 평가척도(Yale Global Tic Severity Scale)를 한국판 가정 평가용 설문지 및 임상 평가용 척도로 개발하기 위하여 본 연구를 시행하였다. 방 법 : 예일 틱 증상 평가척도는 뚜렛 장애 및 기타 틱 장애에서 나타나는 운동틱과 음성틱 각각의 증상의 수, 빈도, 심한 정도, 복합성, 방해 정도 및 장해도를 포괄적으로 평가하도록 고안되어져 있다. 틱 증상을 주소로 정신과외래를 방문한 만 4.3세에서 19세까지의 100명의 환아 및 부모들을 대상으로 한국어로 번역한 예일 틱 증상 평가척도의 가정평가용 설문지를 평가전에 완료하도록 한 후, 면담을 통한 임상평가용 척도를 실시하였으며 수렴타당도 및 변별타당도의 검증을 위해 총괄적인 임상 인상척도-뚜렛 증후군, 강박장애, 주의력결립/과잉운동장애(Clinical Global Impression-TS, OCD, ADHD)를 시행하였다. 결 과 : 자료분석결과 내적일치도, 수렴타당도, 변별타당도 및 검사자간 신뢰도 모두 매우 높게 나타났으며 요인분석상 전 항목척도와 장해도는 운동틱과 음성틱에 해당하는 2개의 요인으로 묶여졌다. 결 론 : 본 연구결과 한국판 예일 틱 증상 평가척도의 높은 타당도 및 신뢰도가 입증되었으며 이는 향후 틱 증상의 객관적인 평가 및 정량화를 위해 유용하게 사용되어질 수 있을 것이다. Objectives : This study was carried out to develop the Korean form of Yale Global Tic Severity Scale(YGTSS)-family & clinical rating version. The severity of motor and phonic tics was rated according to five separate dimensions : number, frequency, intensity, complexity, and interference. Methods : The Korean form of YGTSS was applied to 100 children who visited psychiatric outpatient clinic with chief complaints of tic symptom. Together with YGTSS, Clinical Global Impression for Tourette's syndrome(CGI-TS), Obsessive-Compulsive disorder(CGI-OCD), Attention-Deficit/Hyperactivity Disorder(CGI-ADHD) were administered to all subjects for examining convergent and discriminant validities. Results : We could confirm high internal consistency, convergent and discriminant validities and interrater reliability of YGTSS by analysing data from 100 children with tic disorder. In factor analysis, items were clustered to 2 factors which were identical to motor and phonic tic subscales. Conclusion : The results of this study indicate the Korean form of YGSS is a reliable and valid rating scale for rating tic symptom severity. It can be used to evaluate tic symptom objectively and to quantify the tic severity in the studies for tic disorder.
발열이 동반된 호중구 감소증 환자에서 경험적 치료제로서 cefepime 단독요법과 ceftazidime 단독요법의 효과 비교 연구
이동현,김춘관,고지영,마주락,이가영,천상열,김봉석,노용호 대한화학요법학회 2002 대한화학요법학회지 Vol.20 No.3
발열이 동반된 호중구감소증 환자에서 초기경험적 치료제로서 cefepime은 선택될 수 있다.Cefepime 단독요법은 ceftazidime 단독요법과 비교하여 동등한 임상적 성공률을 보였으나, 향후 더 많은 환자를 대상으로 한 비교연구 및 자료의 보충이 필요하다 하겠다. Background : In view of the recent trend toward monotherapy in the treatment of bacterial infection, we evaluate the clinical efficacy and safety of cefepime versus ceftazidime for the empiric treatment of febrile episodes in cancer patients with chemotherapy-induced neutropenia. METHODS : A prospective, double-blind, randomized study of cefepime 2g every twelve hours and ceftazime 2g every eight hours was performed in 40 adult neutropenic (absolute neutrophil count 〈500/㎣) cancer patients with fever. RESULTS : Forty patients were evaluable. Median duration of neutropenia was 11.5 days in cefepime and 10.5 days in ceftazidime. Treatment was successful in (60%)(12/20) of cefepime-treated patients and (65%)(13/20) of ceftazi야me-treated patients. Overall mortality was 10%(2/20) of cefepime-treated patients and 15% of ceftazidime-treated patients. CONCLUSIONS : Cefepime appears to be as effective as ceftazidime in the initial treatment of febrile episodes in adults cancer patients with chemotherapy-associated neutropenia of modest duration.
김봉석(Bong Seog Kim),김서운(Seo Woon Kim),이영현(Young Hyun Lee),조희준(Hee Jun Cho),이춘택(Choon Taek Lee),도영수(Young Soo Do),김효윤(Hyo Youn Kim),조재일(Jae Ill Zo),심영목(Young Mog Shim),이진오(JIn Oh Lee),강태웅(Tae Woong Kang 대한내과학회 1994 대한내과학회지 Vol.46 No.4
N/A Objective: For curative surgical treatment of esophageal cancer the resectability from the tracheobrochial tree would be the most important factor. Although CT scan has been used for the determination of the resectability of esophageal cancer, it has a limitation on the detection of esophageal cancer invasion to tracheobronchial tree We have performed flexible bronchoscopy in the patients with esophageal cancer to detect and classify the tracheobronchial tree alterations and to find the relation of bronchoscopic findings with the resectability. Method: From April 1990 to October 1992, 133 patients with esophageal cancer had received bronchoscopy. Bronchoscopic findings were classified into three groups: [Group I: normal, Group II: indirect effects (hyperemia and compression-mild, moderate, severe), group III: invasion). CT findings were a]so classified into three classes: [Class A: tumor separated from tracheobronehial tree, Class B: abutting tree, Class C: compressing tree]. We investigated the resectability of esophageal cancer according to bronchoscopic and CT findings. Results: 1) Among 133 patients, the bronchscopic findings were Group I in 41(30.8%), Group II in 66(49.6%), and Group III in 26(19.6%) patients. 2) Abnormal bronchoscopic findings were mainly found in trachea and left main bronchus and frequently found in upper and middle esophageal cancer patients, 3) The resection rate from tracheobronchial tree was 96.8% in group I and 75% in group II bronchoscopic finding. 4) The resections from tracheobronchial tree could be performed in 94.6% of Class A, in 70% of Class B and in 53.8% of Class C of CT scan patients. 5) Six of twelve unresectable patients belonged to Class C of CT scan finding If we excluded Class C in Group II patients, resectability would be increased to 87.5%. Conclusion: We could recommend the operation in esophgeal cancer patients with Group I and minimal Group II bronchoscopic finding. In advanced Group II and/or Class C of CT scan patients, neoadjuvant treatment and reevaluation could be recommended.